Innovative pipeline can transform obesity treatment, says GBI Research
October 8, 2015Research and Development obesity
While the current obesity treatment market has a high level of unmet need, the therapeutic landscape could be transformed by …
Simple blood test can accurately predict imminent heart attacks
October 8, 2015Research and Development NHS, heart attack
A simple blood test which predicts whether a patient suffering chest pains will have a heart attack has the potential to save …
Novartis looks to new measure of Gilenya outcomes
October 8, 2015Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis
Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …
UCB plots new Vimpat submissions after positive monotherapy results
October 8, 2015Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat
A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments. …
Genzyme’s Lemtrada shows five-year efficacy in extended trials
October 8, 2015Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis
Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …
Infectious diseases dominate Nobel Prize awards for medicine
October 8, 2015Manufacturing and Production, Research and Development Nobel Prize, artemisinin, ivermectin, malaria, mectizan, river blindness
Pharma researchers have been awarded the 2015 Nobel Prize for their work on a river blindness treatment, along with work …
Multiple Sclerosis treatment will be a $20bn market by 2024
October 7, 2015Research and Development multiple sclerosis
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion …
Experts call for greater urgency in MS treatment
October 7, 2015Research and Development multiple sclerosis
A therapeutic strategy in multiple sclerosis (MS) that aims to maximise lifelong brain health (neurological reserve) needs to be widely …
PROFILE: Ambitious Ferring wants to be global fertility leader
October 7, 2015Manufacturing and Production, Research and Development Ferring, peptides
The stunning view of the Alps across Lake Geneva from Ferring’s corporate headquarters in Saint-Prex seems appropriate for a company …
AmerisourceBergen acquires sterile compounder PharMEDium for $2.5bn
October 7, 2015Research and Development, Sales and Marketing AmerisourceBergen, mergers and acquisitions
AmerisourceBergen will now source compounded drugs for its hospital clients by manufacturing them itself after spending more than $2.5 billion …
Akebia passes vadadustat for anaemia phase III study with FDA & EMA
October 7, 2015Research and Development Akabia, FDA, anaemia
Akebia Therapeutics has announced the successful completion of the End-of-Phase II Meeting process with the FDA and the Scientific Advice …
Rondo AG appoints Joachim Hoeltz as chief exec
October 7, 2015Manufacturing and Production, Research and Development, Sales and Marketing
Joachim Hoeltz has been appointed chief executive at pharmaceutical packaging company Rondo AG within the Business Area Medipak Systems. He …
NICE approves Merck’s Keytruda for advanced skin cancer following ipilimumab treatment
October 7, 2015Research and Development Merck, NHS, NICE, keytruda, skin cancer
The National Institute for Health and Care Excellence (NICE) has approved Merck’s Keytruda (pembrolizumab) for treating advanced skin cancer after …
Sanofi MS treatment Aubagio slows brain atrophy in Phase III trial
October 7, 2015Research and Development Genzyme, MS, Sanofi
Sanofi and its subsidiary Genzyme have announced that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate …
FDA approves Alkermes schizophrenia treatment
October 6, 2015Research and Development Alkermes, Aristada, FDA, schizophrenia
The US Food and Drug Administration (FDA) has approved Alkermes’s Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada …
Flu jab reduces risk of stroke for two months
October 6, 2015Research and Development flu vaccine, stroke
The risk of suffering a stroke is significantly reduced for up to two months after receiving a flu vaccine, a …
Moving forward in diabetes
October 6, 2015Research and Development Novo Nordiak, diabetes
As many as 387 million people worldwide are living with diabetes, and it is predicted that by 2035 more than …
Novo Nordisk and Diabetes UK extend ‘Clinical Champions’ initiative
October 6, 2015Medical Communications Novo Nordisk, diabetes
Diabetes UK and Novo Nordisk have announced the appointment of 20 Diabetes UK ‘Clinical Champions’, who will be supported and …
David Luther joins MISSION Therapeutics
October 6, 2015Manufacturing and Production, Medical Communications, Sales and Marketing
Cambridge, UK-based MISSION Therapeutics has announced the appointment of David Luther as chief financial officer.Luther brings more than 25 years’ …
Baxter recalls saline after mould contamination
October 6, 2015Manufacturing and Production baxter
Following a number of recalls earlier this year, Baxter has recalled potentially a further 140,000 bags of sodium chloride due …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
